Interneuron regulatory update

The Lexington, Mass., company submitted its formal response to the FDA's February action letter on IPIC's NDA for dexfenfluramine to treat obesity (see BioCentury Feb. 27). IPIC said the

Read the full 294 word article

How to gain access

Continue reading with a
two-week free trial.